68Ga-PSMA-11 PET/CT发现的甲状腺偶发瘤提示前列腺癌甲状腺转移
本文报道一例转移性去势抵抗性前列腺腺癌患者的罕见甲状腺转移病例。68Ga-PSMA-11 PET/CT显示原发前列腺病灶、转移淋巴结及骨骼病灶均强烈表达PSMA,甲状腺结节呈轻度摄取,经进一步检查证实为前列腺腺癌甲状腺转移。
要点
- 68Ga-PSMA-11 PET/CT可用于前列腺癌分期及PSMA表达评估。
- 甲状腺结节在PSMA PET/CT上轻度摄取需警惕前列腺癌转移可能。
- 前列腺癌甲状腺转移临床罕见,但应纳入鉴别诊断。
核心结论
- 68Ga-PSMA-11 PET/CT发现的甲状腺偶发瘤经进一步检查证实为前列腺腺癌甲状腺转移。
研究设计与样本
- 个案报道,描述一例转移性去势抵抗性前列腺腺癌患者的影像学及后续检查结果。
主要发现
- 患者原发前列腺病灶、转移淋巴结及骨骼病灶均显示强烈PSMA表达。
- 甲状腺结节显示轻度PSMA摄取,进一步检查确立为前列腺腺癌甲状腺转移。
临床怎么用
- 前列腺癌患者行68Ga-PSMA-11 PET/CT时,甲状腺结节轻度摄取应进一步评估以排除转移。
局限性
- 为单例个案报道,结论外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
68Ga-labeled prostate-specific membrane antigen (PSMA)-11 PET/CT has evolved as the noninvasive imaging modality of choice in prostatic adenocarcinoma to detect overexpression of PSMA on prostate cancer cells. Metastasis to the thyroid gland is rarely observed in clinical practice of prostatic adenocarcinoma. Herein, we report the first and rare case of metastatic castration-resistant prostatic adenocarcinoma with thyroid metastasis. The patient demonstrated intensely PSMA-expressing primary prostatic lesion, metastatic lymph nodes, and skeletal lesions, and also mild uptake in thyroid nodule, which on further investigations was established as thyroid metastasis from prostate adenocarcinoma.
引用
- Parghane RV, Basu S. Thyroid Incidentaloma on 68Ga-PSMA-11 PET/CT Leading to Detection of Thyroid Metastasis in Metastatic Prostate Carcinoma. Clin Nucl Med. 2022. PMID: 34690291. doi:10.1097/RLU.0000000000003954
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。